Accelerate Genetic Medicine Discovery

Anjarium Biosciences is a cell and gene therapy tools and technology company headquartered in Switzerland.

Our mission is to enable researchers and manufacturers to accelerate the discovery and delivery cycle of new and evolving genetic medicines. Our technology enables our partners to meet biology’s greatest challenges with increasingly flexible and customizable DNA constructs in pursuit of better human health.

Technology

At Anjarium, we help our customers optimize their R&D and manufacturing workflows by delivering synthetic DNA products with unprecedented speed and customization. We deliver faster, cleaner, infinitely flexible, high-fidelity, hairpin-ended, linear, double-stranded DNA products to accelerate the development and delivery of advanced therapies across diverse modalities.

Unmatched speed of production and delivery – in a fraction of the time for traditional plasmid

The scale you need – from microgram to multigram quantities

The highest product consistency, stability, and quality

Customizable terminal DNA structures and complex transgene sequences for a variety of applications

Unmatched speed of production and delivery – in a fraction of the time for traditional plasmid

The scale you need – from microgram to multigram quantities

The highest product consistency, stability, and quality

Customizable terminal DNA structures and complex transgene sequences for a variety of applications

Unique structural integrity unlocks functional applications

We have designed a one-pot reaction that generates linear, double-stranded DNA with customizable hairpin-ended structures. The integrity of the DNA sequence of interest is protected by these structures, which are inspired by nature and play a functional role in certain applications.

Innovative Solutions in Synthetic DNA and Vector Production

Explore Anjarium Biosciences' cutting-edge advancements in synthetic DNA and vector production technologies. Our detailed technical posters highlight the innovative methods and superior performance of our proprietary DNA and Resin products across various applications, including gene therapy, Adeno-associated Virus (rAAV) vector production, mRNA production, and lentiviral vector production and purification. Discover how our solutions are revolutionizing the gene and cell therapy field with higher efficiency, purity, and scalability, driving the next generation of biomedical research and clinical development.

Versatile Synthetic DNA for Cell and Gene Therapy

This poster highlights Anjarium's innovative synthetic DNA as a superior alternative to traditional plasmid DNA for cell and gene therapy applications. It showcases the versatility of our platform to produce high-purity DNA for mRNA, AAV, and lentivirus vector production, and for in vivo transgene expression. The poster emphasizes the benefits of Anjarium's DNA, including higher fidelity, purity, and functional performance compared to conventional DNA vectors.

Download

Superior Synthetic DNA for rAAV Manufacturing

This poster shows Anjarium's innovative synthetic DNA to be a superior alternative for recombinant Adeno-associated virus (rAAV) production. It highlights the advantages of Anjarium’s DNA over conventional plasmid DNA, including higher viral titers, higher percentages of full particles, and avoidance of unwanted backbone sequences. The poster emphasizes the superior performance of Anjarium’s DNA in manufacturing ssAAV and scAAV across various serotypes and production scales, demonstrating its effectiveness in gene therapy applications.

Download

Advanced Synthetic DNA for Superior mRNA Production

This poster details Anjarium's novel synthetic DNA specifically designed for in vitro transcription (IVT) to produce high-potency mRNA. We have developed synthetic DNA with a stable polyA tail of 140 nucleotides in length. Anjarium DNA allows the production of mRNA at superior yield, purity, and potency when compared to traditional plasmid DNA.

Download

Innovative Synthetic DNA for Efficient Lentiviral Vector Production

Anjarium_Synthetic_DNA_LVV_Manufacturing.pdf-2

This poster outlines Anjarium's novel synthetic DNA specifically designed for Lentiviral vector (LVV) production. It highlights the advantages of Anjarium DNA over traditional plasmid DNA, including our exclusively enzymatic production process, higher purity, scalability, speed, and flexibility. The poster details the process, benefits, and results of using Anjarium DNA in LVV production, showcasing its effectiveness in developing gene therapy applications, particularly in generating chimeric antigen receptor (CAR) T-cells.

Download

Innovative ANJ-Resin for Enhanced Lentiviral Vector Purification

Anjarium Biosciences novel Resin technology uses anion exchange chromatography to achieve lentiviral vector (LVV) purification. It demonstrates superior performance vs. traditional DEAE-Resin, by achieving higher virus recovery rates, enhanced purity, and effective contaminant clearance at nearly physiological pH and salt concentrations. With significant improvements in LVV downstream processing, Anjarium’s novel Resin offers a robust solution for increasing demands in gene therapy applications.

Download

Services

Infinitely flexible, highly scalable synthetic DNA customized to support your needs

We offer a range of products to support research, development, and commercialization of genetic medicines.

Our cell-free platform creates pure, customizable, and flexible synthetic linear DNA constructs for a wide variety of therapeutic modalities – all scaled to your needs.

Why are our products different?

Purity
Unlike with plasmid-based systems, no bacterial sequences are used in production, reducing the risk of unwanted elements and DNA backbone components in end product

Scale
Our process scales from microgram to multigram batches while using a small bioreactor and minimal reagents

Speed
Production time from circular DNA template to vial delivery of weeks rather than months for plasmid-based techniques

Stability
Hairpin-ended structures protect the integrity of the double-stranded DNA sequences

Flexibility
Complex and customized transgene sequences beyond what can be delivered by bacteria-derived DNA

Solutions

What can we do for you?

Discovery

Preclinical

Clinical

Commercial

RUO

Catalog products
Bespoke products
Candidate screening

In vivo testing
Toxicity studies

GMP

In vivo testing
Toxicity studies

HQ GMP
GMP

GMP

Discovery

RUO

Catalog products
Bespoke products
Candidate screening

GMP

Preclinical

RUO

In vivo testing
Toxicity studies

GMP

In vivo testing
Toxicity studies

Clinical

RUO

GMP

HQ GMP
GMP

Commercial

RUO

GMP

Schlieren: Innovation and R&D center

Analytical development and QC fully equipped
Executing according to ISO9001 principles

Basel: GMP manufacturing facility

GMP certification in progress
RUO, HQ GMP, and GMP
Swissmedic awarded advanced therapy medical products (ATMP) license for cell therapy production in 2022

AAV

ITR stability with significant improvement in yields
Catalog: Rep/Cap and Helper, Luciferase and GFP reporters in multiple serotypes
Bespoke: GOI, Helper and Rep/Cap with full serotype capabilities

mRNA

Less DNA required for equivalent yields
Catalog: Luciferase and GFP reporters
Bespoke sequences with stable Poly-A tails up to 140+

Lentivirus

Production of all constructs including GOI with long terminal repeat (LTR) sequences

HDR and other applications

Design and manufacturing services to create custom constructs

AAV

ITR stability with significant improvement in yields
Catalog: Rep/Cap and Helper, Luciferase and GFP reporters in multiple serotypes
Bespoke: GOI, Helper and Rep/Cap with full serotype capabilities

mRNA

Less DNA required for equivalent yields
Catalog: Luciferase and GFP reporters
Bespoke sequences with stable Poly-A tails up to 140+

Lentivirus

Production of all constructs including GOI with long terminal repeat (LTR) sequences

HDR and other applications

Design and manufacturing services to create custom constructs

Team

Our team of innovative scientists and manufacturing experts are relentless problem-solvers committed to creating new possibilities for genetic medicines through synthetic, enzymatically produced DNA.

Our Leadership team and Board of Directors bring deep development, manufacturing, and commercialization experience from leading global life science companies.

Leadership

Board of Directors

Otmane Boussif

Chief Technology Officer

View Bio

Nate Massari

Chief Business Officer

View Bio

Stephen Yoo

Chief Executive Officer

View Bio

Douglas Fambrough

Former CEO, Dicerna Pharmaceuticals

View Bio

Bali Muralidhar

Managing Partner and Chief Investment Officer, Abingworth

View Bio

Claudio Nessi

Managing Director, Omega Funds

View Bio

Gaurav Shah

CEO, Rocket Pharmaceuticals

View Bio

Bram Vanparys

Managing Partner, Gimv

View Bio

Stephen Yoo

CEO, Anjarium Biosciences

View Bio

Investors

Anjarium is proud to partner with leading life science investors.

Investors include Abingworth, Gimv, Omega Funds, Pfizer Ventures, and Surveyor Capital (a Citadel company).

Careers

Join us to accelerate the development and delivery of novel, life-changing medicines to patients.

Anjarium is assembling a world-class global team to accelerate access to revolutionary cell and gene therapies with next generation tools and technology.

See Current Openings

News & Events

News

Events

7 May 2024

Anjarium Biosciences Presents Data Demonstrating Novel Synthetic DNA Applications for Cell and Gene Therapies at 27th Annual ASGCT Meeting

8 December 2022

Anjarium Biosciences appoints Chief Technology Officer

18 October 2022

Anjarium Biosciences appoints Chairperson and Non-executive Director

12 July 2022

Anjarium Biosciences appoints experienced industry executives

14 June 2022

Anjarium Biosciences appoints Chief Executive Officer

16 September 2021

Anjarium Biosciences Raises CHF 55.5M ($61M) Series A Financing

May 2024

Visit us at ASGCT, Booth #312

7-11 May, 2024

ASGCT | Baltimore, MD

October 2024

Visit with us at Cell & Gene Meeting on the Mesa

7-9 October, 2024

Meeting on the Mesa | Phoenix, AZ

October 2024

Visit us at ESGCT

22-25 October, 2024

ESGCT | Rome, Italy

DNA to Catalyze Your Advanced Therapies

Anjarium Biosciences is a cell and gene therapy tools and technology company headquartered in Switzerland.

Technology

The benefits of the Anjarium DNA platform include:

Unique structural integrity unlocks functional applications

Innovative Solutions in Synthetic DNA and Vector Production

Services